Sort   by:  
 Page size 
TranscriptomicsMicroRNA expression in peripheral blood predicts poor and prolonged response to sunitinib.
Peripheral blood samples were taken before initiation of therapy and 2 weeks later from patients with advanced renal cell carcinoma treated with sunitinib in first line. MicroRNA expression in peripheral blood was assessed using microarrays and several models predicting poor response and prolonged r...
ORGANISM(S): Homo sapiens 
2013-02-11 | E-GEOD-32099 | biostudies-arrayexpress
TranscriptomicsMGMT modulates glioblastoma angiogenesis and response to the tyrosine kinase inhibitor sunitinib
Angiogenesis inhibitors, such as sunitinib, represent a promising strategy to improve glioblastoma (GBM) tumor response. In this study, we used the O6-methylguanine methyltransferase (MGMT)-negative GBM cell line U87MG stably transfected with MGMT (U87/MGMT) to assess whether MGMT expression affects...
ORGANISM(S): Homo sapiens 
2012-09-11 | E-GEOD-40776 | biostudies-arrayexpress
ProteomicsAmiloride reduces FN3K expression to restore sunitinib sensitivity in renal cell carcinoma
The kidney is a vital organ responsible for water and sodium metabolism, while the primary function of amiloride is to promote the excretion of water and sodium. We investigated amiloride enhanced the sunitinib sensitivity in RCC. We found both sunitinib and amiloride displayed cytotoxicity and exer...
ORGANISM(S): Homo Sapiens 
2024-05-07 | PXD052100 |
ProteomicsQuantitative phosphoproteomics of chronic sunitinib treated renal cell carcinoma 786-O cells with GPR30 agonist G-1
In this project, we generated chronic sunitinib-treated 786-O cell, a renal cell carcinoma cell line. In order to investigate the possible effect of GPR30 agonist, G-1, on the growth-inhibtion related signaling pathways, we treated either parental both parental and chronic sunitinib-treated 786-O ce...
ORGANISM(S): Homo sapiens (Human) 
2021-04-28 | PXD021254 | Pride
Renal cell carcinoma Sunitinib Gpr30 
TranscriptomicsDifferentially expressed genes analysis between dihydroberberine, sunitinib and dihydroberberine plus sunitinib.
To gain insights into the mechanisms of dihydroberberine, sunitinib and dihydroberberine plus sunitinib on inhibition to A549 cells, we have employed whole genome microarray expression profiling as a discovery platform to identify different genes between dihydroberberine, sunitinib and dihydroberber...
ORGANISM(S): Homo sapiens 
2015-06-26 | E-GEOD-70282 | biostudies-arrayexpress
ProteomicsTransgelin contributes to a poor response of metastatic renal cell carcinoma to sunitinib treatment
Renal cell carcinoma (RCC) represents about 2-3% of all cancers with over 400,000 new cases per year. Sunitinib, a vascular endothelial growth factor tyrosine kinase receptor inhibitor, has been used mainly for first-line treatment of metastatic clear-cell RCC with good or intermediate prognosis. Ho...
ORGANISM(S): Homo sapiens (Human) 
2021-11-03 | PXD027065 | Pride
Mccrcc  sunitinib  resistance  dia-ms  transgelin 
ProteomicsCardiac Metabolic Deregulation Induced by the Tyrosine Kinase Receptor Inhibitor Sunitinib is rescued by Endothelin Receptor Antagonism
The growing field of cardio-oncology addresses the side effects of cancer treatment on the cardiovascular system. Here, we explored the cardiotoxicity of the antiangiogenic therapy, sunitinib, in the mouse heart from a diagnostic and therapeutic perspective. We showed that sunitinib induces an anaer...
ORGANISM(S): Mus musculus (Mouse) 
2017-07-14 | PXD006888 | Pride
Cardiotoxicity Sunitinib Positron emission tomography Endothelin Cardio-oncology Echocardiography Macitentan 
TranscriptomicsAnalysis of Gene Expression of Human Renal Cell Carcinoma by DNA Microaray in Patients treated with Sunitinib. An Exploratory Study
Gene Evaluation of DNA expression from snap-frozen renal cell cancer tissue from 5 patients with locally advanced non-metastatic tumors, submitted to nephrectomy after being treated with 2 cycles of neoadjuvant Sunitinib were compared to match controls comprising of 6 patients with no neoadjuvant in...
ORGANISM(S): Homo sapiens 
2015-05-11 | E-GEOD-68629 | biostudies-arrayexpress
TranscriptomicsGene expression profiles of Sunitinib-treated but not untreated short-term serum-free cultures predict treatment response of human high-grade gliomas in vitro
High-grade gliomas are amongst the most deadly human tumors. Treatment results are overall disappointing. Nevertheless, in several trials around 20% of patients respond to therapy. Diagnostic strategies to identify those patients that will ultimately profit from a specific targeted therapy are urgen...
ORGANISM(S): Homo sapiens 
2014-10-07 | E-GEOD-51305 | biostudies-arrayexpress
TranscriptomicsEffect of Sunitinib treatment withdrawal on Immunodeficient mice bearing MDA-MB231 tumors
Immunodeficient RAG1-/- mice bearing MDA-MB231-LUC+ tumors of 50-70 mm3 were daily administrated by gavage with vehicle (containing, 0.5% carboxymethylcellulose, 1.8 % NaCl, 0.4 % Tween-80, 0.9 %. benzyl alcohol, and ultrapure water adjusted to pH 6.0) or sunitinib (40mg/kg/day) for 30 days followed...
ORGANISM(S): Mus musculus 
2014-08-24 | E-GEOD-50795 | biostudies-arrayexpress
Sort   by:  
 Page size